Sanofi’s Sarclisa has received approval in more than 50 nations for multiple indications. Credit: rafaelnlins/Shutterstock.

Sanofi has received China’s National Medical Products Administration (NMPA) approval for the use of Sarclisa (isatuximab), combined with a standard-of-care regimen to treat adults with newly diagnosed multiple myeloma (NDMM) who are not eligible for autologous stem cell transplant (ASCT).

The approval is based on the positive outcomes of the IMROZ Phase III trial, which showed that the therapy, when used with bortezomib, lenalidomide and dexamethasone (VRd), improved progression-free survival compared to VRd alone.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Sanofi Oncology global head Olivier Nataf stated: “This approval, occurring just weeks after Sarclisa’s first in the country, represents tremendous progress towards advancing this mission. Now patients with multiple myeloma and their providers have access to two new Sarclisa-based regimens that have the potential to improve outcomes across lines of therapy.”

The recent approval comes shortly after the NMPA’s December 2024 decision to approve Sarclisa plus pomalidomide and dexamethasone (Pd) for adults with relapsed or refractory MM who have undergone a minimum of one previous therapy, including lenalidomide and a proteasome inhibitor.

Sarclisa is a cluster of differentiation 38 (CD38) monoclonal antibody.

In the Asia-Pacific region, Japan is currently reviewing a regulatory submission for the antibody in NDMM subjects who are not eligible for haematopoietic stem cell transplantation.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Sarclisa has received approval in more than 50 regions and countries including the European Union, Japan, China and the US, for multiple indications.

Sanofi is dedicated to the patient-centric clinical development of the antibody, with several Phase II and Phase III studies underway across the MM treatment spectrum, covering six potential indications.

The company is also exploring a subcutaneous administration method for the antibody in trials.

Sarclisa’s non-proprietary name in the US is isatuximab-irfc, following US Food and Drug Administration guidance for the industry on the naming of biological products.

In December 2024, Sanofi and SK bioscience broadened their partnership to jointly develop pneumococcal conjugate vaccines (PCVs) for paediatric and adult populations.